Pathophysiology of anthracycline- and radiation-associated cardiomyopathies: implications for screening and prevention
- PMID: 15856486
- DOI: 10.1002/pbc.20352
Pathophysiology of anthracycline- and radiation-associated cardiomyopathies: implications for screening and prevention
Abstract
Great progress has been made in treating childhood cancers over the past 40 years. Along with second malignancies, a major complication of anti-cancer therapies is adverse cardiovascular effects, especially cardiomyopathy and coronary artery disease. The pathophysiology and characteristics of cardiomyopathy associated with radiation therapy and anthracycline therapy are distinctive. We describe each type of cardiomyopathy, along with its risk factors. These distinctive cardiomyopathies require different screening tests. Appropriate screening of the entire cardiovascular system should be performed because radiation and chemotherapy affect the entire system. Prevention recommendations focus on cardiomyopathy and coronary artery disease.
Copyright 2005 Wiley-Liss, Inc.
Similar articles
-
Pathology of radiation and anthracycline cardiotoxicity.Pediatr Blood Cancer. 2005 Jun 15;44(7):630-7. doi: 10.1002/pbc.20346. Pediatr Blood Cancer. 2005. PMID: 15825155 Review.
-
Present risk of anthracycline or radiation-induced cardiac sequelae following therapy of malignancies in children and adolescents.Klin Padiatr. 2009 May-Jun;221(3):162-6. doi: 10.1055/s-0029-120722. Epub 2009 May 12. Klin Padiatr. 2009. PMID: 19437364
-
Anthracycline cardiotoxicity in long-term survivors of childhood cancer.Cardiovasc Toxicol. 2007;7(2):122-8. doi: 10.1007/s12012-007-0006-4. Cardiovasc Toxicol. 2007. PMID: 17652816 Review.
-
Exposure to anthracyclines during childhood causes cardiac injury.Semin Oncol. 2006 Jun;33(3 Suppl 8):S8-14. doi: 10.1053/j.seminoncol.2006.04.019. Semin Oncol. 2006. PMID: 16781284 Review.
-
Dexrazoxane for the prevention of cardiomyopathy in anthracycline treated pediatric cancer patients.Pediatr Blood Cancer. 2005 Jun 15;44(7):584-8. doi: 10.1002/pbc.20358. Pediatr Blood Cancer. 2005. PMID: 15700251 Review.
Cited by
-
Late Cardiotoxicity: Issues for Childhood Cancer Survivors.Curr Treat Options Cardiovasc Med. 2016 Jul;18(7):47. doi: 10.1007/s11936-016-0466-6. Curr Treat Options Cardiovasc Med. 2016. PMID: 27230282 Review.
-
Current Views on Anthracycline Cardiotoxicity in Childhood Cancer Survivors.Pediatr Cardiol. 2015 Aug;36(6):1112-9. doi: 10.1007/s00246-015-1176-7. Epub 2015 May 5. Pediatr Cardiol. 2015. PMID: 25939787 Free PMC article. Review.
-
Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection.Antioxid Redox Signal. 2013 Mar 10;18(8):899-929. doi: 10.1089/ars.2012.4795. Epub 2012 Oct 12. Antioxid Redox Signal. 2013. PMID: 22794198 Free PMC article. Review.
-
Cardiovascular Risk in Childhood Cancer Survivors.Biomedicines. 2022 Dec 1;10(12):3098. doi: 10.3390/biomedicines10123098. Biomedicines. 2022. PMID: 36551851 Free PMC article. Review.
-
Identification of novel hypermethylated or hypomethylated CpG sites and genes associated with anthracycline-induced cardiomyopathy.Sci Rep. 2023 Aug 4;13(1):12683. doi: 10.1038/s41598-023-39357-2. Sci Rep. 2023. PMID: 37542143 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
